Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I think it would only fall that low on very murky data. They would have to blow through a ton of SLs to hit that. I would be "que sera-sera-ing" long before that.
This is the right opportunity. The right well-discovered, founder-game-planed, Perfect CEO-garnered opportunity. Professor Missling is not
@#$%ing around with his chosen career path, believe me. He has better things to do...he's worth $40M without Anavex.
§
Excellent man! See? Now THATS the spirit!
http://www.forbes.com/sites/jonathansherman/2011/03/21/how-individuals-can-beat-institutional-investors/#56619428a753
http://www.investopedia.com/articles/trading/08/institutional-effect.asp
Down...set....
§
On that I agree with you wholeheartedly scottsmith.§
Oh for Heaven's sake DOLPHY! We will be moving into a P3. The current trial will run for three full years. A3-71 is a 4th generation compound, fully protected, and ready for clinical development. Exploratory developments in Rett's, epilepsy, MS, FTD and Parkinson's. Running tight on a 37MM O/S that won't flinch at 100% dilution if the next phase stands any chance of being successful.
Abandoned us? When your CEO sends in the air squadrons to strafe the battlefield you're going to be left quivering in your foxhole soldier!
I suggest you load your weapon.
§
Ha Ha Ha! Giving all that credit to one little promotional article? That's hilarious! This MB did 1000% more to promote AVXL in that same time!!! WE SHOULD ALL BE CHARGED AND GO TO JAIL!!!!
Picture-perfect gap close and all should have increased their positions/reduced avg by the corresponding 23%. (Except those who's positions are to large for the piddly volume....)
Only closers!
§
Gee, directors are taking options @ 5.60
http://ih.advfn.com/p.php?pid=nmona&article=71317051
Must be a while before they're planning on "dumping".
Unfortunately, Dr Favus's equity reports are seldom leaked to the retailer and never for sale. Not that anyone listens to Elliot Favus, of course.
§
Sorry...just stumbled onto this board on my way home...HIC! I'll leave now, I'm gonna wretch!
§
Must be using one of them newfangled 3-D printers this time!
Authorized Shares 7,520,000,000 a/o Mar 26, 2016
'Bout a sucker per share last four days...lmao
§
HOW on earth...can this be???
Capital Change=shs decreased by 1 for 1000 split. Pay date=09/04/2015.
Authorized Shares 7,520,000,000 a/o Mar 26, 2016
Outstanding Shares 1,939,867,115 a/o Apr 11, 2016
Can you really go from 1BB to 100MM to 2BB in 6 months? That's friggin' majik!!! Gotta hand it to ya FINRA, you've outdone yourself
§
Have not. Will put it in the queue. 1558...funny bits!
OT from another board:
That is interesting. An MRI contrast scan costs about $3000US. Scans are not listed in the study record. I wonder who is paying for them. Perhaps the guy buying 1558 shares every day?
Affiliates have 2 days to report.
The CCS session is titled "Advanced Clinical Studies with Drugs for the Treatment of Alzheimer’s and Parkinson’s Disease". The presentation simply titled "ANAVEX-2-73, a Sigma-1 Receptor Agonist". Getting some preclinical A2-73 PD data there might not be out of the question.
https://www.michaeljfox.org/foundation/grant-detail.php?grant_id=785
I have not looked into details of this experiment.
Ziggydmz1: Hahaha! Love it! German vital records start in 1558.
Letter to King Henry II
"The famous open Letter to King Henry II of France by Nostradamus is his dedicatory preface to the now-missing 1558 edition of his Propheties,"
§
16:23:08 5.48 1558
§
Yes, that thread was at the root of it. I would wager the MRI footage was stock. The whole AU media bump could be geared toward keeping the next phase based there. In that case it could be Dr Macfarlane is promoting a brain scan endpoint measure of the next trial with some observations not included in the protected data of this trial?
Scans will surely be part of a WellDesignedDoubleBlindRandomizedPlaceboControlledPivitolStudy, right?
§
RecklessSpeculation?
Bears have been in control of biotech all year:
http://etfdb.com/type/sector/healthcare/biotechnology/
AVXL YTD:-13.46%
None too shabby...savvy?
§
The commentator says:
"Macfarlane said that preliminary brain scans show..."
There was eligibility criteria of "A brain CT or MRI scan performed within last 12 months from day of screening consistent with the clinical diagnosis of probable AD" but no other scans are indicated.
Could have some of the participants had scans recently outside of the trial tests that showed promising results? Or is the bubbly newscaster just calling EEG/ERP a 'brain scan'?
Where would we be without that Monday lift? 4.80?
“Thy sin’s not accidental, but a trade.” -W.Shakespeare - Measure For Measure
§
That is my thinking also...the short-long part. So, even if she's painting again, is she also suddenly wondering why she's in the kitchen with a tube of Burnt Sienna in her hand???
The disease modifying part is going to be a real stickler. Without it we might skate-by on better than the leading brands. If it's there it will be a miracle drug and I will buy a small country.
§
You mean this?
"Similar positive MMSE score effect and no notable difference between ANAVEX 2-73 alone and ANAVEX 2-73 with donepezil (ANAVEX PLUS) were observed."
I don't know what this is supposed to infer. Sounds like a comparison of the minority donepezil-naive group and majority don-stabilized group. But there is no distinction made in any results. I have only ever read "most who are already taking donepezil".
The suit looks like a Regent.
§
I thought it sounded rather...cautiously optimistic...?
He chose to use the word "cure", not us!
§
I want it to be Bayer, that's probably the truth. Xena's Japan rationale is very plausible also. Just so many different possibilities. I think, though, once a compound is licensed-out, that defines the direction the company chooses to take in their business plan. Here I think we will do a sacrificial deal(s) with 2-73 to fund 3-71 and other compounds and remain our own flagship. The affiliates are young.
Missling, Metzner...Bayer seems a natural connection, I guess. Metrifonate failed, they sold florbetaben.
What on Earth are you guys talking about? §
It's only a shelf registration. A final prospectus supplement (424B3) will precede a request by the company for effectiveness.
Now if that has been delayed because of an investigation, that is another matter. That we don't know.
Perhaps there is an unusual delay and that combined with a (possible) SEC investigation spells doom. I'm not qualified to say either way.
I think the $150M figure is the magic number. That is what Missling is looking for in up-front Phase 3 development funds. The S-3 is just a demonstration that we can raise the funds ourselves, if necessary. It also provides publicly-disclosed base prospectus info as part of a non-deal roadshow.
I am also convinced the little redhead did not go to the ball without her suitor waiting and ready. We'd still be OTC.
It's all coming...according to plan.
§
This is very bullish for the MF.
The head and by lines:
"Could a Pill to Cure Alzheimer's Disease Become Available Soon?
After taking an experimental pill developed by Anavex Life Sciences, two women with Alzheimer's have regained their ability to play piano and paint. How soon until it could be available for everyone with the disease?"
These comments:
"It's important to note here that Anavex's 2-73 does not function in the same manner as any Alzheimer's candidates that have been put through placebo-controlled studies."
"A much more sensible (and financially responsible) option would be to license 2-73 to a larger company with the means to run a such a large and expensive trial."
"Anavex has no shortage of presentations and press releases suggesting its efficacy,..."
It reads as a setup to a bullish stance in the future, IMO.
It's publicity...beer me!
§
I agree. Speaking of anecdotal evidence when you know how little it can mean can seem like trying to preempt some unfavorable data. But by the same token, if you know the data is good but can't speak of that, you say something you can.
Certainly if the company was accepting offers they would have sold by now and skated with the money and the compounds would be under development by a bigger firm. So many less developed and proven drugs/companies have been bought for 100s of millions, even billions.
We're still here because Uncle Tom is not giving up! And Missling has met his milestones and not failed so far.
§
Yeah, I kind of read that tweet to mean "hold on I'm working on some real dirt" and we'll see it soon.
"The sun'll come out tomorrow..."
§
While I do not think the PI is a spokesperson for the company, I would think if they wanted his silence that would be part of a working agreement.
I think Missling, in his skill set capacity, is willing to use the media to his advantage IF he firmly believes the outcome will justify the risks. That is part of being a masterful game player..using all the cards. And I don't think Macfarlane would go out on a limb like this after the Prana debacle. He's seen the data.
There will be results to back up this hype, IMO.
We will see this:
"This prospectus provides you with a general description of the securities offered. We will file prospectus supplements and may provide other offering material at later dates that will contain specific terms of each offering of securities by us. These supplements may also add, update or change information contained in this prospectus."
Before we see this:
"The registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933 or until the registration statement shall become effective on such date as the Commission, acting pursuant to said Section 8(a), may determine."
Anavex has done nothing wrong. The SEC is not investigating the company for having drug candidates in clinical trials. Good grief!
AF knows this is contingency financing and Anavex will partner A2-73 for final development and marketing.
Amatuer17:
1. This is the third LP deal we have signed. They haven't killed us yet, or provided more than $2M to the coffers.
2. What scottsmith said! Heptares was for sale.
§
From the perspective of the science, the results, and the FDA acceptance of that being what ultimatly matters.
The media coverage is unnesessary promotion, IMO. If it provides a boost in pps, that's great. But it does not provide one lick of validation. If similar anecdotal reports appear across a majority of the participants, backed by data, I will hoop and holler.
I did have some thoughts on the subject, though. Perhaps this is a good place to air them.
If a majority of the participants were already stabalized on Donepezil, which is less effective over time, not much in the early results of the PLUS trial could be attributed to the Donepezil alone. It was either an additive effect of the A2-73, or it alone.
Now Donepezil has some pretty nasty reported side effects, as far as mood goes, after extended usage. ie:
http://www.askapatient.com/viewrating.asp?drug=20690&name=ARICEPT
This is a typical Aricept/Donepezil review page. There are lots of them.
We don't know exactly how many of these trial participants are not on Donepezil, perhaps some stopped taking the Donepezil, whether that is allowed, etc. It could be that the A2-73 mitigates the side effects of Donepezil as well as enhances it's effectiveness. It could be the A2-73 all on it's own. We just won't know without some clinical data. Counting up the people reported improved means nothing. The entire cohort could dance and sing in front of an FDA panel and they might still say, "Nice placebo effect".
If you believe in the company swing those highs and lows and accumulate for the future, but don't call media attention proof of anything until it's post-results.
Oh, come-on now!
http://news.pennmedicine.org/blog/2014/01/memory-may-fade-with-dementia-but-artist-abilities-and-benefits-carry-on.html
http://www.everydayhealth.com/alzheimers-disease/artistic-ability-unaffected-by-dementia-study-says.aspx
http://www.medicaldaily.com/art-therapy-and-dementia-how-creativity-helps-unlock-alzheimers-patients-thoughts-and-fears-254301
§
Boo-ya! Got em...
§
And the sources cited by Dr Maurice for the trial design:
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm080571.pdf
This is a critical read if you want to understand why extensive PK/PD analysis can take quite some time:
http://www.fda.gov/downloads/Drugs/Guidances/UCM072137.pdf
§
I had forgotten this one. So very informative and word of mouth:
http://seekingalpha.com/article/3687706-anavex-interview-professor-tangui-maurice
Too bad you needed to be God KKD, and those other guys just need BoS degrees. Your coverage will be missed.
Pleiotropy
§
OK, admit I had a few milly .004s They're gone. Just a radar trade and by the time I DDd and read the board it was wheeew-eee! Glad I'm outta here!
How the heck is this trading @ .001? Big, fat bloated worthless shell waiting to R/S your asses into oblivion.
What a mess. Mr Shaw, you're a worthle....ohnevermind...
§
JBG, what happened to the count? You have never failed to report. Are you ok?
§VTVT in!
16/04/24 +1,000 6.3424 -$6,343 +1,000
That matches Ms Aussie's statements. Sabbatical likely meaning intensive 12 week testing was over and some time to step out of the hospital and do other things...like visit patients! Nice "home side" manner.
Nice price action today. The hedgies doled-out the shares on open and they just let it ride. And Papa Troll was busy making that stupid boinky-boink sound all day!
He'll probably catch up and write some smear and they will walk it down into real news, but there's not much legs here to chop, unlike Nov, as others have pointed out.
Power 10? I say 6.23...
§
ed- I know...conservative, right? Never underestimate the traders, though.